Table 2 Comparison of gene mutations between AML patients with and without MDS-R mutations.
Categories | Variables | Total cohort (N = 1213) | Younger population | Older population | ||||
|---|---|---|---|---|---|---|---|---|
Without MDS-R mutations (n = 525, 76.6%) | With MDS-R mutations (n = 160, 23.4%) | P value | Without MDS-R mutations (n = 291, 55.1%) | With MDS-R mutations (n = 237, 44.9%) | P value | |||
Activated signaling | FLT3-ITDHigh a,b | 152 (12.5%) | 76 (14.6%) | 16 (10.0%) | 0.146 | 35 (12.0%) | 25 (10.5%) | 0.594 |
FLT3-ITDLow a,b | 93 (7.7%) | 48 (9.2%) | 8 (5.0%) | 0.094 | 25 (8.6%) | 12 (5.1%) | 0.114 | |
FLT3-TKD | 91 (7.5%) | 37 (7.0%) | 14 (8.8%) | 0.492 | 22 (7.6%) | 18 (7.6%) | >0.999 | |
KIT | 57 (4.7%) | 34 (6.5%) | 8 (5.0%) | 0.576 | 14 (4.8%) | 1 (0.4%) | 0.002 | |
NRAS | 169 (13.9%) | 76 (14.5%) | 22 (13.8%) | 0.898 | 39 (13.4%) | 32 (13.5%) | >0.999 | |
KRAS | 51 (4.2%) | 28 (5.3%) | 7 (4.4%) | 0.837 | 8 (2.7%) | 8 (3.4%) | 0.800 | |
PTPN11 | 69 (5.7%) | 30 (5.7%) | 8 (5.0%) | 0.845 | 17 (5.8%) | 14 (5.9%) | >0.999 | |
Tumor suppressor | TP53 | 111 (9.2%) | 25 (4.8%) | 10 (6.3%) | 0.420 | 60 (20.6%) | 16 (6.8%) | <0.001 |
WTI | 79 (6.5%) | 50 (9.5%) | 10 (6.3%) | 0.263 | 14 (4.8%) | 5 (2.1%) | 0.106 | |
PHF6 | 34 (2.8%) | 8 (1.5%) | 10 (6.3%) | 0.003 | 4 (1.4%) | 12 (5.1%) | 0.020 | |
NPM1 | 257 (21.2%) | 116 (22.1%) | 5 (3.1%) | <0.001 | 103 (35.4%) | 33 (13.9%) | <0.001 | |
DNA methylation | IDH1 | 77 (6.3%) | 31 (5.9%) | 6 (3.8%) | 0.423 | 22 (7.6%) | 18 (7.6%) | >0.999 |
IDH2 | 148 (12.2%) | 38 (7.2%) | 25 (15.6%) | 0.003 | 42 (14.4%) | 43 (18.1%) | 0.284 | |
DNMT3A | 216 (17.8%) | 83 (15.8%) | 23 (14.4%) | 0.709 | 73 (25.2%) | 37 (15.6%) | 0.007 | |
TET2 | 162 (13.4%) | 40 (7.6%) | 7 (4.4%) | 0.210 | 51 (17.5%) | 64 (27.0%) | 0.011 | |
Cohesin complex genes | STAG2 | 57 (4.7%) | 0 (0%) | 16 (10.0%) | <0.001 | 0 (0%) | 41 (17.3%) | <0.001 |
RAD21 | 25 (2.1%) | 17 (3.2%) | 3 (1.9%) | 0.591 | 2 (0.7%) | 3 (1.3%) | 0.661 | |
SMC1A | 18 (1.5%) | 11 (2.1%) | 2 (1.3%) | 0.743 | 4 (1.4%) | 1 (0.4%) | 0.257 | |
SMC3 | 9 (0.7%) | 3 (0.6%) | 2 (1.3%) | 0.332 | 3 (1.0%) | 1 (0.4%) | 0.631 | |
Transcription factor | CEBPAdouble mutations | 103 (8.5%) | 73 (13.9%) | 12 (7.5%) | 0.039 | 10 (3.4%) | 8 (3.4%) | >0.999 |
CEBPA bZIP in-frame | 121 (10.0%) | 87 (16.6%) | 16 (10.0%) | 0.042 | 11 (3.8%) | 7 (3.0%) | 0.603 | |
GATA2 | 84 (6.9%) | 41 (7.8%) | 15 (9.4%) | 0.513 | 14 (4.8%) | 14 (5.9%) | 0.697 | |
ETV6 | 18 (1.5%) | 6 (1.1%) | 6 (3.8%) | 0.039 | 2 (0.7%) | 4 (1.7%) | 0.416 | |
RUNX1 | 165 (13.6%) | 0 (0%) | 60 (37.5%) | <0.001 | 0 (0%) | 105 (44.3%) | <0.001 | |
Chromatin modifiers | ASXL1 | 161 (13.3%) | 0 (0%) | 57 (35.6%) | <0.001 | 0 (0%) | 104 (43.9%) | <0.001 |
BOCR | 32 (2.6%) | 0 (0%) | 16 (10.0%) | <0.001 | 0 (0%) | 16 (6.8%) | <0.001 | |
EZH2 | 19 (1.6%) | 0 (0%) | 7 (4.4%) | <0.001 | 0 (0%) | 12 (5.1%) | <0.001 | |
Spliceosome complex genes | SF3B1 | 33 (2.7%) | 0 (0%) | 10 (6.3%) | <0.001 | 0 (0%) | 23 (9.7%) | <0.001 |
SRSF2 | 80 (6.6%) | 0 (0%) | 8 (5.0%) | <0.001 | 0 (0%) | 72 (30.4%) | <0.001 | |
U2AF1 | 41 (3.4%) | 0 (0%) | 23 (14.4%) | <0.001 | 0 (0%) | 18 (7.6%) | <0.001 | |
ZRSR2 | 18 (1.5%) | 0 (0%) | 5 (3.1%) | 0.001 | 0 (0%) | 13 (5.5%) | <0.001 | |
